Moreover, in digestive high-grade neuroendocrine neoplasms (HG-NEN), specific DDR gene mutations like TP53 and BRAF have shown predictive value for response to cisplatin-based chemotherapy [22]. Here, TP53 is linked to neuroendocrine neoplasm.